GSK awarded Arrow declaration in patent dispute with Vectura

The English High Court has ruled in favour of GSK in its patent dispute with Vectura, a UK-based pharmaceutical company which specialises in inhalable medicaments.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

GSK ordered to pay Vectura $89.7m in patent damages

7 May 2019 British drugmaker Vectura has succeeded in its patent litigation against fellow UK pharmaceutical company GlaxoSmithKline over a series of drugs delivered through GSK’s ‘Ellipta’ dry powder inhaler.

Africa

Hikma and Vectura collaborate to develop GSK generics

12 November 2018 Jordan-based Hikma Pharmaceuticals and British pharmaceutical company Vectura Group have united to develop generic versions of GSK’s Ellipta respiratory products.

Americas

Vectura sues GSK for patent infringement

29 July 2016 Pharmaceutical company Vectura has sued GSK for allegedly infringing its patent after claiming that it refused to expand on a licensing agreement.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

GSK awarded Arrow declaration in patent dispute with Vectura

More on this story

Editor's picks

Editor's picks

More features